Equities researchers at William Blair issued their Q1 2026 earnings estimates for FibroGen in a research report issued on Tuesday, April 1st. William Blair analyst A. Hsieh expects that the ...
William Blair dropped their Q2 2025 earnings estimates for ON in a report released on Tuesday, April 1st. William Blair analyst D. Carden now anticipates that the company will post earnings per share ...
CEO Ashe emphasized confidence in the company's ability to manage evolving tariff impacts through strategic pricing and supply chain dexterity. AIS's focus remains on growth and margin expansion, ...
Valmont said it has comprehensive plans to mitigate the impact of tariffs on imports from Mexico, Canada and China, as well ...
On Friday, William Blair analysts downgraded Valmont Industries (NYSE:VMI) from Outperform to Market Perform. The decision comes after a meeting with the company’s management, where concerns were ...
Investing.com -- William Blair raised DocuSign (NASDAQ:DOCU) to Outperform in a note Monday, highlighting optimism around the company’s Intelligent Agreement Management (IAM) platform and its ...
Investing.com -- William Blair analysts issued a cautionary note on Palantir Technologies (NASDAQ:PLTR), highlighting potential downside risk for the stock despite continued commercial momentum.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback